Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

NCT01264432 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm
Peritoneal Carcinomatosis
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Quality-of-Life Assessment
RADIATION: Radiation Therapy
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)